CAPR

3.93

2.08% 0.08

Dopo l'orario di chiusura: 3.94 0.010 +0.25%

Capricor Therapeutics Inc (CAPR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CAPR Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$3.85

Aprire:

$3.85

Volume 24 ore:

3.35M

Relative Volume:

1.80

Capitalizzazione di mercato:

$227.59M

Reddito:

$11.13M

Utile/perdita netta:

$-114.59M

Rapporto P/E:

-1.6991

EPS:

-2.313

Flusso di cassa netto:

$-113.96M

1 W Prestazione:

-5.76%

1M Prestazione:

-81.73%

6M Prestazione:

-83.76%

1 anno Prestazione:

-49.71%

Intervallo 1D:

$3.73

$3.998

Intervallo di 1 settimana:

$3.73

$4.70

Portata 52W:

$2.96

$40.37

Capricor Therapeutics Inc Stock (CAPR) Company Profile

Nome

Capricor Therapeutics Inc

Settore

Healthcare (1079)

Industria

Biotechnology (602)

Telefono

(310) 358-3200

Indirizzo

10865 ROAD TO THE CURE, SAN DIEGO, CA

Dipendente

231

Cinguettio

@Capricor

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

CAPR's Discussions on Twitter

Compare CAPR vs VRTX, REGN, ARGX, RVMD, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CAPR Capricor Therapeutics Inc	3.93	405.09M	11.13M	-114.59M	-113.96M	-2.313
VRTX Vertex Pharmaceuticals Inc	529.65	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	797.00	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	864.74	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	205.55	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	359.27	33.81B	5.76B	514.49M	1.10B	4.4813

Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-30	Iniziato	Alliance Global Partners	Buy
2025-06-26	Iniziato	B. Riley Securities	Buy
2025-05-20	Iniziato	Roth Capital	Buy
2024-10-21	Iniziato	Piper Sandler	Overweight
2024-05-17	Iniziato	Oppenheimer	Outperform
2024-01-05	Iniziato	Cantor Fitzgerald	Overweight
2022-10-26	Iniziato	Ladenburg Thalmann	Buy
2018-12-26	Downgrade	Maxim Group	Buy → Hold
2018-01-26	Reiterato	H.C. Wainwright	Buy
2017-09-15	Reiterato	H.C. Wainwright	Buy
2017-02-13	Ripresa	Rodman & Renshaw	Buy
2016-07-06	Ripresa	H.C. Wainwright	Buy
2016-06-15	Iniziato	ROTH Capital	Buy

Mostra tutto

Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie

Jul 28, 2026

This Analyst Slashed CAPR Stock’s Target By 86% – But, Retail Bulls Say Setup Offers An Attractive Risk-Reward - Yahoo Finance

Jul 28, 2026

Capricor Therapeutics Faces Severe Stock Decline Amid FDA Concer - GuruFocus

Jul 28, 2026

CAPR Investor Alert: Capricor Therapeutics Investors Encouraged t - The National Law Review

Jul 28, 2026

Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount (NASDAQ:CAPR) - Seeking Alpha

Jul 28, 2026

Capricor Stock Tanks On FDA AdCom NotesWhat Investors Should Know (NASDAQ:CAPR) - Seeking Alpha

Jul 28, 2026

Replimune joins Capricor in post-briefing doc drop (REPL:NASDAQ) - Seeking Alpha

Jul 28, 2026

Alliance Global Partners Reiterates "Neutral" Rating for Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat

Jul 28, 2026

B. Riley Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $10 From $63 - marketscreener.com

Jul 28, 2026

Roth Capital Downgrades Capricor Therapeutics to Neutral From Buy, Adjusts PT to $7 From $38 - Moomoo

Jul 28, 2026

FDA panel raises doubts over Capricor’s deramiocel data ahead of DMD review - The Pharma Letter

Jul 28, 2026

CAPR|Capricor Therapeutics Inc|Price:7.000|Chg%:-12.700 - TradingKey

Jul 28, 2026

BREAKING: Capricor Therapeutics Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Learn More - Supply Chain Digital

Jul 28, 2026

Biotech Firms Face Critical FDA Review Events - Intellectia AI

Jul 28, 2026

Capricor’s Deramiocel Briefing Is a Masterclass in How Not to Define an Endpoint - The Clinical Trial Vanguard

Jul 28, 2026